Therapeutic Rationale
The rationale for co-administering low-dose methylphenidate in combination with a CFS Nutrient Formula to CFS patients is as follows. The CFS Nutrient Formula provides antioxidants, amino acids and mitochondrial cofactors that enhance the efficacy of mitochondrial functioning while the low-dose CNS stimulant provides the necessary catalyst (i.e. spark) to augment the metabolism of this fuel and the production of cellular energy. In other words, the high-potency CFS Nutrient Formula supports the functioning of the nervous, immune, and endocrine systems to a level at which the drug is able to produce a positive clinical effect on CFS symptoms without further depleting or degrading these systems.

Low-Dose Stimulant Drug
The drug component of the treatment utilizes an already marketed, generic version of methylphenidate hydrochloride (Ritalin®). This drug has been in clinical use for over 50 years with a well-described safety profile when use by skilled medical personnel. It has been extensively studied and used as a treatment for people with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy since its US approval in 1955. The Synergy Trial will utilize a dosage of methylphenidate (5-10mg twice daily) that is appreciably less than the average dosage recommended by the drug’s manufacturer.

High-Potency Nutrients
The CFS Nutrient Formula is composed of vitamins, antioxidants, amino acids, and therapeutic dosages of key nutrients that support brain and mitochondrial functioning. The CFS Nutrient Formula is designed to support immune and nervous system functioning in order to enhance the safety and efficacy of the low-dose medication. The CFS Nutrient Formula is not yet currently available as a commercial product. Please see below for a list of the ingredients contained in the CFS Nutrient Formula: